GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance

In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody‐drug conjugate (ADC), tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Inase, Aki, Maimaitili, Yimamu, Kimbara, Shiro, Mizutani, Yu, Miyata, Yoshiharu, Ohata, Shinya, Matsumoto, Hisayuki, Kitao, Akihito, Sakai, Rina, Kawaguchi, Koji, Higashime, Ako, Nagao, Shigeki, Kurata, Keiji, Goto, Hideaki, Kawamoto, Shinichiro, Yakushijin, Kimikazu, Minami, Hironobu, Matsuoka, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928658/
https://www.ncbi.nlm.nih.gov/pubmed/36819180
http://dx.doi.org/10.1002/jha2.600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928658/
https://www.ncbi.nlm.nih.gov/pubmed/36819180
http://dx.doi.org/10.1002/jha2.600

Ejemplares similares